Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9806
Title: The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.
Authors: Shackleton, Mark;Davis, Ian D;Hopkins, Wendie;Jackson, Heather M;Dimopoulos, Nektaria;Tai, Tsin;Chen, Qiyuan;Parente, Phillip;Jefford, Michael;Masterman, Kelly-Anne;Caron, Dania;Chen, Weisan;Maraskovsky, Eugene;Cebon, Jonathan S
Affiliation: Cancer Vaccine Laboratory, Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, 3084, Australia.
Issue Date: 23-Sep-2004
Citation: Cancer Immunity 2004; 4(): 9
Abstract: Dendritic cells (DCs) show promise as adjuvants in anticancer immunotherapeutic strategies. Flt3 ligand (FL) is a hematopoietic growth factor that increases the number of immature DCs in the blood and other tissues. We treated 27 patients with metastatic or high-risk resected melanoma with s.c. FL daily for 14 d in three 28 d cycles. Eighteen of these patients also received vaccination with influenza (Flu), Melan-A (Mel), tyrosinase (Tyr), and NY-ESO-1 peptides. To induce local DC maturation, 8 of the vaccinated patients had imiquimod, a Toll-like receptor-7 ligand (TLR7L), applied topically to their vaccine sites. Patients were monitored for clinical and hematological effects. Immune responses were assessed by cutaneous reactivity to vaccination and by the induction of peptide-specific CD8+ T-cells. Eight patients did not complete the protocol due to adverse events related to their cancer. The treatment was generally safe and well tolerated, although some patients developed clinically significant toxicities related to FL. FL induced increases in immature CD11c+ and CD123+ peripheral blood (PB) DCs. Other hematological effects included monocytosis, granulocytosis, and thrombocytosis, which were marked in some patients. Cutaneous reactions to peptide vaccination and circulating peptide-specific CD8+ T-cells were more frequent in imiquimod-treated patients. FL treatment of melanoma patients has pleiotropic clinical and hematological effects. In vivo maturation of FL-generated DCs using imiquimod may increase immune responses to tumor antigens.
Internal ID Number: 15384929
URI: http://ahro.austin.org.au/austinjspui/handle/1/9806
URL: http://www.ncbi.nlm.nih.gov/pubmed/15384929
Type: Journal Article
Subjects: Adjuvants, Immunologic.administration & dosage.adverse effects
Adult
Aged
Aminoquinolines.administration & dosage.adverse effects.immunology
Antigens, Neoplasm.immunology
Antineoplastic Agents.administration & dosage.adverse effects
CD8-Positive T-Lymphocytes.immunology
Cancer Vaccines.administration & dosage.adverse effects.immunology
Cytokines.blood.immunology
Dendritic Cells.immunology
Female
Humans
Immunotherapy, Active.methods
MART-1 Antigen
Male
Melanoma.immunology.therapy
Membrane Proteins.administration & dosage.adverse effects.immunology
Middle Aged
Monophenol Monooxygenase.immunology
Neoplasm Proteins.immunology
Peptide Fragments.administration & dosage.adverse effects.immunology
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.